Influenza Tests Devices Market Size was valued at USD 0.38 Billion in 2022. The Influenza Tests Devices Market industry is projected to grow from USD 0.41 Billion in 2023 to USD 0.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.00% during the forecast period (2023 - 2032). The increasing prevalence of influenza, the emergence of technologically advanced influenza diagnostics, and the growth in research funding for influenza diagnostics are expected to be a significant market driver for the Influenza Tests Devices Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Influenza Tests Devices is being driven by the rising prevalence of influenza and the growing geriatric population. Epidemic influenza poses a significant public health challenge each season. The World Health Organization (WHO) estimates that influenza has a severe impact on three to five million individuals annually, resulting in 250,000 to 500,000 deaths. Children experience the highest attack rate, while complications such as hospitalization and death are most prevalent in the elderly.
The increasing geriatric population raises the likelihood of a higher incidence of flu. Consequently, the WHO recommends vaccination for individuals aged 65 and above to prevent influenza cases. According to the Centers for Disease Control and Prevention, the U.S. witnessed 9 million flu cases, 4 million influenza-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu-related deaths during the 2021–2022 season. Similar to previous seasons preceding the COVID-19 outbreak, 83% of fatalities were among older individuals. The weakened immune system of older adults makes them more susceptible to the flu virus.
As a result, it is anticipated that throughout the projection period, demand for the Influenza Tests Devices Market will increase due to the rising prevalence of influenza, and the growing geriatric population. Thus, driving the Influenza Tests Devices Market revenue.
The Influenza Tests Devices Market segmentation, based on Tests includes Influenza Multiplex NAATs, Influenza Antigen Tests, and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs). The influenza multiplex NAATs segment dominated the market, accounting for 58% of market revenue (0.06 Billion). Second-generation Nucleic Acid Amplification Tests (NAATs) typically exhibit enhanced sensitivity, often surpassing 95%, and offer rapid test times ranging from 5 to 90 minutes. The potential advantages of rapid NAAT Point-of-Care Tests (POCTs) for individuals include early initiation of antiviral treatment, with optimal benefits observed when administered within 48 hours, as well as a reduction in the unnecessary use of antibiotics, minimizing exposure to unwanted side effects for patients.
Figure 1: Influenza Tests Devices Market, by Tests, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Influenza test devices market in North America can be attributed to several key factors. The rising disease prevalence in the U.S. is anticipated to propel market expansion. According to the Centers for Disease Control and Prevention (CDC), the 2021-2022 influenza season resulted in 9 million illnesses, 4 million medical visits, 10,000 hospitalizations, and 5,000 fatalities. The flu season occurred in two waves, with the second wave experiencing a higher number of hospitalizations. The expected rise in awareness regarding the significance of flu vaccinations and early detection is also poised to foster market expansion.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: INFLUENZA TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Influenza Tests Devices Market accounts for the second-largest market share as the anticipated high prevalence of influenza is set to be a driving factor for the regional market throughout the forecast period. In the 2022−2023 season, sentinel primary care providers in the EU/EEA tested 81,800 specimens for the influenza virus, with 19,538 (24%) testing positive. This marked a more than four-fold increase in influenza virus detections from sentinel sources compared to the 2021−2022 season and represented the highest number of detections over the past four seasons. For instance, during the pre-pandemic season of 2019−2020, a total of 11,978 specimens tested positive. Further, the German Influenza Tests Devices Market held the largest market share, and the UK Influenza Tests Devices Market was the fastest-growing market in the European region
The Asia-Pacific Influenza Tests Devices Market is expected to grow at the fastest CAGR from 2023 to 2032. The regional market is poised for rapid growth, driven by increasing awareness and acceptance of influenza diagnostic kits. In 2021, the incidence of influenza virus infections in China declined significantly to approximately 47.4 per 100,000 people from the peak observed in 2019. Notably, the Ministry of Health, Labor, and Welfare released figures for September 11–17, based on reports from 5,000 designated medical institutions, revealing 34,665 influenza cases—an increase of 1.57 times compared to the previous week, averaging 7.03 cases per institution. Additionally, the growing governmental support for the approval of new diagnostic tests for influenza contributes to the expansion of the influenza diagnostics market in the Asia-Pacific region. Moreover, China’s Influenza Tests Devices Market held the largest market share, and the Indian Influenza Tests Devices Market was the fastest-growing market in the Asia-Pacific region.
Influenza Tests Devices Market Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Influenza Tests Devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Influenza test devices industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Influenza test devices industry to benefit clients and increase the market sector. In recent years, the Influenza test devices industry has offered some of the most significant advantages to the healthcare sector, enabling rapid and accurate diagnosis of influenza infections, leading to timely treatment and effective management of the disease. Major players in the Influenza Tests Devices Market, including Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of medical equipment, analytical instruments, reagents, and consumables, as well as software and services addressing complex analytical challenges in research, diagnostics, and clinical laboratories. The company offers solutions in cellular analysis, biology, flow cytometry, and synthetic biology, with a product range covering mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research. Thermo Fisher serves diverse sectors including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic labs, and government agencies, along with the environmental, industrial quality, and process control sectors. Its distribution channels include direct sales, e-commerce, and third-party distributors across the Americas, Asia-Pacific, and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher Scientific acquired Mesa Biotech, a leading developer and manufacturer of next-generation molecular diagnostic tests, in January 2021 for USD 450 million. This strategic acquisition enhances Thermo Fisher Scientific's test portfolio by incorporating Mesa's PCR-based Accula rapid point-of-care test platform for SARS-CoV-2, RSV, Influenza A and B, and Strep A
Becton Dickinson and Co. (BD) is a medical technology company specializing in the manufacturing and sale of medical devices, reagents, and instruments. Its diverse product portfolio includes syringes, pen needles, intravenous catheters, infusion pumps, automated medication dispensing systems, respiratory ventilation equipment, diagnostic tools, and more. BD caters to various sectors, including life science researchers, healthcare institutions, clinical laboratories, the pharmaceutical industry, and the general public. The company operates globally, with a presence in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Headquartered in New Jersey, USA, BD recently received emergency use authorization from the U.S. Food and Drug Administration in February 2023 for a novel molecular diagnostic combo test targeting influenza A + B, aiming to address diseases during the current and upcoming respiratory virus seasons.
Key companies in the Influenza Tests Devices Market include
Influenza Tests Devices Industry Developments
August 2022:Seegene initiated a campaign to provide routine syndromic PCR testing for COVID-19, influenza A and B, and respiratory syncytial virus (RSV) in specific settings across European and Asian markets. This proactive campaign, named In-Life PCR, was launched to proactively address potential surges in the transmission of COVID-19 and other respiratory viruses resulting from the relaxation of public health precautions and increased travel.
March 20218:Sekisui Diagnostics formed a collaboration with Mesa Biotech, a leading developer and manufacturer of next-generation molecular diagnostic tests, to introduce the Silaris Influenza A and B tests.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.38 Billion |
| Market Size 2023 | USD 0.41 Billion |
| Market Size 2032 | USD 0.70 Billion |
| Compound Annual Growth Rate (CAGR) | 7.00% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Tests, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc |
| Key Market Opportunities | Advancements in genomics technologies |
| Key Market Dynamics | Rising prevalence of chronic diseases |
Frequently Asked Questions (FAQ) :
The Influenza Tests Devices Market size was valued at USD 0.38 Billion in 2022.
The Influenza Tests Devices Market is projected to grow at a CAGR of 7.00% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in the market are Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, Thermo Fisher Scientific Inc
The Influenza Multiplex NAATs segment dominated the market in 2022.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
ยฉ 2024 Market Research Future ยฎ (Part of WantStats Reasearch And Media Pvt. Ltd.)
